Atb Cap Markets Expects Reduced Earnings for Organigram

Key Points

• Atb Cap Markets has decreased its FY2025 earnings estimate for Organigram Holdings from $0.10 to $0.07 per share, while the consensus estimate is $0.16 per share.
• Organigram's stock has experienced a 6.1% decline in trading, opening at C$2.01, with a 52-week low of C$1.22 and a high of C$2.84.
• The company, a licensed producer of cannabis products in Canada, has a market capitalization of C$248.32 million and a debt-to-equity ratio of 3.07.

Organigram Holdings Inc. (TSE:OGI - Free Report) - Equities research analysts at Atb Cap Markets lowered their FY2025 earnings per share estimates for Organigram in a report released on Wednesday, August 13th. Atb Cap Markets analyst F. Gomes now anticipates that the company will post earnings per share of $0.07 for the year, down from their prior estimate of $0.10. The consensus estimate for Organigram's current full-year earnings is $0.16 per share. Atb Cap Markets also issued estimates for Organigram's FY2027 earnings at $0.06 EPS.

Organigram Price Performance

Shares of TSE OGI traded up C$0.07 during mid-day trading on Monday, reaching C$2.14. The company had a trading volume of 155,247 shares, compared to its average volume of 173,049. Organigram has a one year low of C$1.22 and a one year high of C$2.77. The company has a debt-to-equity ratio of 3.07, a quick ratio of 2.62 and a current ratio of 3.36. The business's 50-day simple moving average is C$1.96 and its 200 day simple moving average is C$1.77. The firm has a market cap of C$264.38 million, a price-to-earnings ratio of -4.52, a PEG ratio of 0.42 and a beta of 1.13.

About Organigram

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.